Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Neonatal Fc receptor antagonist efgartigimod safely and sustainably reduces IgGs in humans.

Autor: Ulrichts P; argenx BVBA, Zwijnaarde, Belgium., Guglietta A; argenx BVBA, Zwijnaarde, Belgium., Dreier T; argenx BVBA, Zwijnaarde, Belgium., van Bragt T; argenx BVBA, Zwijnaarde, Belgium., Hanssens V; argenx BVBA, Zwijnaarde, Belgium., Hofman E; argenx BVBA, Zwijnaarde, Belgium., Vankerckhoven B; argenx BVBA, Zwijnaarde, Belgium., Verheesen P; argenx BVBA, Zwijnaarde, Belgium., Ongenae N; argenx BVBA, Zwijnaarde, Belgium., Lykhopiy V; argenx BVBA, Zwijnaarde, Belgium., Enriquez FJ; argenx BVBA, Zwijnaarde, Belgium., Cho J; Department of Molecular and Cellular Medicine, Texas A&M University Health Science Center, College Station, Texas, USA., Ober RJ; Department of Molecular and Cellular Medicine, Texas A&M University Health Science Center, College Station, Texas, USA.; Department of Biomedical Engineering, Texas A&M University, College Station, Texas, USA., Ward ES; Department of Molecular and Cellular Medicine, Texas A&M University Health Science Center, College Station, Texas, USA.; Department of Microbial Pathogenesis and Immunology, Texas A&M University Health Science Center, Bryan, Texas, USA., de Haard H; argenx BVBA, Zwijnaarde, Belgium., Leupin N; argenx BVBA, Zwijnaarde, Belgium.

Publikováno v: The Journal of clinical investigation [J Clin Invest] 2018 Oct 01; Vol. 128 (10), pp. 4372-4386. Date of Electronic Publication: 2018 Jul 24.